Payment overview · 2025
General Payments
$912.61
27 reported records · 10 companies
Healthcare provider profile · identity verified
Mark Scheier, MD.
Allopathic & Osteopathic Physicians|Family Medicine · LA PALMA, CA · NPI 1073516076
Verified facts
What the public records show
CMS Open Payments records show Mark Scheier, MD. received $912.61 in general payments during 2025 across 27 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 37.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Caplyta, Farxiga, Gemtesa, Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Caplyta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 220 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trulicity by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Nuedexta by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $344.61 | 37.8% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $256.68 | 28.1% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $128.22 | 14.1% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $37.76 | 4.1% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $33.87 | 3.7% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $28.93 | 3.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $26.88 | 3.0% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $20.41 | 2.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $19.77 | 2.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.48 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $912.61 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $344.61 | 11 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $186.70 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $114.21 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $80.62 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $64.96 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $58.17 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $33.87 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $28.93 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $26.88 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $19.77 | 1 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $14.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 220 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 61 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
220 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 310 | 58 |
| Metformin Hcl | Metformin Hcl | 272 | 54 |
| Furosemide | Furosemide | 270 | 48 |
| Levothyroxine Sodium | Levothyroxine Sodium | 255 | 35 |
| Jardiance | Empagliflozin | 220 | 26 |
| Gabapentin | Gabapentin | 209 | 43 |
| Simvastatin | Simvastatin | 205 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 193 | 48 |
| Lisinopril | Lisinopril | 181 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 161 | 34 |
| Ibuprofen | Ibuprofen | 155 | 41 |
| Eliquis | Apixaban | 144 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 142 | 31 |
| Losartan Potassium | Losartan Potassium | 142 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 140 | 35 |
| Potassium Chloride | Potassium Chloride | 136 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 135 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 125 | 36 |
| Famotidine | Famotidine | 114 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 111 | 28 |
| Glipizide | Glipizide | 109 | 18 |
| Clozapine | Clozapine | 105 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 93 | 14 |
| Omeprazole | Omeprazole | 92 | 22 |
| Risperidone | Risperidone | 72 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | suppressed |
| Glimepiride | Glimepiride | 71 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 70 | 26 |
| Meloxicam | Meloxicam | 68 | 19 |
| Cephalexin | Cephalexin | 64 | 35 |
| Januvia | Sitagliptin Phosphate | 64 | 12 |
| Divalproex Sodium | Divalproex Sodium | 62 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 61 | 21 |
| Mounjaro | Tirzepatide | 61 | suppressed |
| Carvedilol | Carvedilol | 59 | 13 |
| Divalproex Sodium Er | Divalproex Sodium | 59 | suppressed |
| Azithromycin | Azithromycin | 58 | 30 |
| Nystatin | Nystatin | 58 | 14 |
| Xarelto | Rivaroxaban | 56 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 17 |
| Olanzapine | Olanzapine | 55 | 11 |
| Baclofen | Baclofen | 54 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 12 |
| Atenolol | Atenolol | 51 | 15 |
| Myrbetriq | Mirabegron | 51 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 48 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 47 | suppressed |
| Spironolactone | Spironolactone | 47 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 43 | suppressed |
| Trulicity | Dulaglutide | 42 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 39 | suppressed |
| Rybelsus | Semaglutide | 39 | suppressed |
| Bupropion Xl | Bupropion Hcl | 37 | suppressed |
| Lactulose | Lactulose | 36 | suppressed |
| Mirtazapine | Mirtazapine | 36 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | suppressed |
| Finasteride | Finasteride | 34 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 34 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 33 | 11 |
| Sertraline Hcl | Sertraline Hcl | 33 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Latanoprost | Latanoprost | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Naproxen | Naproxen | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Caplyta | Lumateperone Tosylate | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Prednisone | Prednisone | 25 | suppressed |
| Allopurinol | Allopurinol | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Kerendia | Finerenone | 21 | suppressed |
| Amantadine | Amantadine Hcl | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 14 |
| Linzess | Linaclotide | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 14 |
| Topiramate | Topiramate | 20 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 19 | suppressed |
| Permethrin | Permethrin | 19 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Olanzapine Odt | Olanzapine | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 16 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 15 | suppressed |
| Clozapine Odt | Clozapine | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $912.61 · 27 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, EMBLAVEO, FANAPT, FARXIGA, GEMTESA, JARDIANCE, MOUNJARO, REXULTI, TEFLARO, VERQUVO | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Caplyta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error